Julie Beck

April 05, 2012 | Inside Counsel

A little more than a week after Nike sued rival athletic wear maker Reebok over its sale of unauthorized apparel featuring National Football League quarterback Tim Tebow, it has prevailed.

By Julie Beck

2 minute read

April 03, 2012 | Inside Counsel

Microsoft is heading for the hills, fleeing Germany for fear of what an upcoming court ruling may do to its business.

By Julie Beck

1 minute read

April 02, 2012 | Inside Counsel

We know that the unpaid interns are disgruntled, but other uncompensated workers in the media have been striking back toonamely the unpaid bloggers that contribute to The Huffington Post.

By Julie Beck

2 minute read

March 30, 2012 | Inside Counsel

We have seen a lot of evidence of late that working professionals these days have to be careful with what they say and do on social media.

By Julie Beck

2 minute read

March 29, 2012 | Inside Counsel

The magnetic pull of Tim Tebow was just too much for Reebok to resist.

By Julie Beck

1 minute read

March 28, 2012 | Inside Counsel

The FUP oil workers unionBrazils largest oil workers federationbrought its own civil lawsuit against the companies on Tuesday.

By Julie Beck

2 minute read

March 27, 2012 | Inside Counsel

A district court in Los Angeles ruled Friday that concert business Live Nation does not have a monopoly on rock show tickets, though it made no ruling on whether its emails still have a monopoly on my inbox.

By Julie Beck

2 minute read

March 26, 2012 | Corporate Counsel

1st Circuit narrows application of SOX whistleblower protection provision

By Julie Beck

11 minute read

March 26, 2012 | Corporate Counsel

Class action waiver cannot block plaintiffs from pursuing claims; Internal complaints are protected activity under the FLSA; District court mishandled discovery in discrimination case; Solvent companies must pay benefits of insolvent affiliate

By Julie Beck

10 minute read

March 26, 2012 | Inside Counsel

A district court denied biopharmaceutical company AstraZenecas request for a preliminary injunction that would delay generic versions of its anti-psychotic drug Seroquel from entering the market.

By Julie Beck

2 minute read